Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ANL
stocks logo

ANL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast ANL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANL is USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ANL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANL is USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 1.200
sliders
Low
9.00
Averages
High
9.00
Current: 1.200
sliders
Low
9.00
Averages
High
9.00
H.C. Wainwright
Buy -> Neutral
downgrade
2025-06-02
Reason
H.C. Wainwright
Price Target
2025-06-02
downgrade
Buy -> Neutral
Reason
H.C. Wainwright downgraded Adlai Nortye to Neutral from Buy.
H.C. Wainwright
Joseph Pantginis
Buy -> Neutral
downgrade
$9
2025-06-02
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$9
2025-06-02
downgrade
Buy -> Neutral
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Adlai Nortye Ltd (ANL.O) is -3.33, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Adlai Nortye Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.29
Current PE
-3.33
Overvalued PE
-2.16
Undervalued PE
-6.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.21
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.43
Undervalued EV/EBITDA
-3.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.21
Current PS
0.00
Overvalued PS
5.09
Undervalued PS
-4.66
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ANL News & Events

Events Timeline

Sign Up For More Events
no data image
No Data
Sign Up For More Events

News

[object Object]
Preview
1.0
11-21Newsfilter
Adlai Nortye Set to Attend Upcoming Investor Conferences

  • Investor Conferences Participation: Adlai Nortye Ltd. will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the 36th Oppenheimer Annual Healthcare Life Sciences Conference on February 25-26, 2026.

  • Company Overview: Adlai Nortye is a clinical-stage biotechnology company focused on developing innovative cancer therapies, with a pipeline that includes next-generation immunotherapies and RAS-targeting therapies.

  • Forward-Looking Statements: The announcement includes forward-looking statements regarding the company's expectations and plans, which are subject to risks and uncertainties that could affect actual results.

  • Contact Information: For further inquiries, investors can contact Adlai Nortye's Investor Relations via email at ir@adlainortye.com.

[object Object]
Preview
9.0
10-22Newsfilter
Adlai Nortye to Discuss AN4035 Preclinical Findings at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Treatments

  • Presentation Announcement: Adlai Nortye Ltd. will present its novel CEACAM5-targeting antibody-drug conjugate (ADC), AN4035, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.

  • Key Findings: AN4035 showed strong cytotoxicity in specific cancer cell lines, achieved a 73% objective response rate in a patient-derived xenograft trial, and demonstrated a favorable toxicology profile in preclinical studies.

  • Therapeutic Potential: The ADC is designed to minimize systemic toxicities associated with current pan-RAS(ON) inhibitors, aiming to improve efficacy and broaden the therapeutic window for treating RAS-addicted tumors.

  • Company Overview: Adlai Nortye is a clinical-stage biotechnology company focused on innovative cancer therapies, with a portfolio that includes next-generation PD-1/L1 modulation and RAS-targeted therapies.

[object Object]
Preview
4.0
06-03Benzinga
HC Wainwright & Co. Downgrades Adlai Nortye to Neutral

  • Real-time Trading Intelligence: Benzinga Pro offers the fastest and most accurate stock market news alerts to help traders succeed in their investments.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights generated by Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Adlai Nortye Ltd (ANL) stock price today?

The current price of ANL is 1.2 USD — it has decreased -11.76 % in the last trading day.

arrow icon

What is Adlai Nortye Ltd (ANL)'s business?

Adlai Nortye Ltd. is a Cayman Islands-based investment holding company. The Company is involved in the research and development of pharmaceutical products. It is a clinical-stage company focused on the development of targeted and immune-modulating cancer therapies. It is advancing an oncology pipeline, with Buparlisib (AN2025), a pan-phosphoinositide 3-kinase (PI3K) inhibitor, being evaluated in a registrational Phase three trial (NCT04338399) for patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC) that has progressed after prior anti-programmed death-ligand 1 (PD-L1) treatment. It is also advancing multiple drug candidates, including AN4005, an oral small molecule PD-L1 inhibitor; AN8025, a multifunctional fusion protein acting as a T cell and antigen-presenting cell (APC) modulator; and AN9025, an oral small molecule pan-rat sarcoma virus (RAS) inhibitor. The Company’s subsidiary, Alpine Bioscience Ltd. (Alpine BVI), is an investment holding company.

arrow icon

What is the price predicton of ANL Stock?

Wall Street analysts forecast ANL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANL is  USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Adlai Nortye Ltd (ANL)'s revenue for the last quarter?

Adlai Nortye Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Adlai Nortye Ltd (ANL)'s earnings per share (EPS) for the last quarter?

Adlai Nortye Ltd. EPS for the last quarter amounts to -0.57 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Adlai Nortye Ltd (ANL)'s fundamentals?

The market is revising No Change the revenue expectations for Adlai Nortye Ltd. (ANL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -31.43%.
arrow icon

How many employees does Adlai Nortye Ltd (ANL). have?

Adlai Nortye Ltd (ANL) has 123 emplpoyees as of December 05 2025.

arrow icon

What is Adlai Nortye Ltd (ANL) market cap?

Today ANL has the market capitalization of 44.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free